Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays

Journal Article · · Journal of Nuclear Medicine
OSTI ID:478323
; ;  [1]
  1. Washington Univ. School of Medicine, St. Louis, MO (United States); and others

The purpose of this study was to assess the results of PET with 16{alpha}-[{sup 18}F]fluoro-17 {beta}-estradiol (FES) and [{sup 18}F]fluoro-2-deoxy-D-glucose (FDG) to validate the concordance between tumor estrogen-receptor (ER) status as determined by FES-PET and in vitro assays and to assess the relationship between tumor metabolic activity determined by FDG-PET and tumor ER status, both of which may provide information about tumor aggressiveness and prognosis. We studied 32 patients with primary breast masses and 21 patients with clinical or radiological evidence of recurrent/metastic breast carcinoma. A diagnosis of breast carcinoma was subsequently proven in 43 patients (24 primary, 15 metastic and 4 recurrent tumors). In vitro assessment of ER status was available for 40 malignant lesions (23 primary and 17 metastatic/recurrent). The patients underwent PET with both FES and FDG, and the uptake of each tracer within each lesion was evaluated qualitatively as well as semiquantitatively using the standardized-uptake-value (SUV) method. We found good overall agreement (88%) between in vitro ER assays and FES-PET. This degree of agreement is similar to that observed between replicate in vitro assays (with discordances due to interlaboratory, interassay and specimen variability). We were, however, unable to demonstrate any significant relationship between tumor FDG uptake and ER status or between tumor FDG and tumor FES uptake in these patients. These results indicate that in vitro ER assays and/or FES-PET provide unique direct information about breast cancer ER status that cannot be obtained indirectly by FDG-PET. 25 refs., 5 figs., 2 tabs.

DOE Contract Number:
FG02-84ER60218
OSTI ID:
478323
Journal Information:
Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: 10 Vol. 36; ISSN 0161-5505; ISSN JNMEAQ
Country of Publication:
United States
Language:
English

Similar Records

FDG-PET/CT in the evaluation of anal carcinoma
Journal Article · Sat Jul 01 00:00:00 EDT 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20842901

Breast cancer: PET imaging of estrogen receptors
Journal Article · Sat Oct 01 00:00:00 EDT 1988 · Radiology; (United States) · OSTI ID:6702656

FDG-PET evaluation of indeterminate pancreatic masses
Journal Article · Wed May 01 00:00:00 EDT 1996 · Journal of Computer Assisted Tomography · OSTI ID:457535